Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
SHR Neuro Krebs Kardio Lipid Stoffw Microb
Hoeppner, J; Zirlik, K; Brunner, T; Bronsert, P; Kulemann, B; Sick, O; Marjanovic, G; Hopt, UT; Makowiec, F.
Multimodal treatment of locally advanced esophageal adenocarcinoma: which regimen should we choose? Outcome analysis of perioperative chemotherapy versus neoadjuvant chemoradiation in 105 patients.
J Surg Oncol. 2014; 109(3):287-93
Doi: 10.1002/jso.23498
Web of Science
PubMed
FullText
FullText_MUG
- Co-Autor*innen der Med Uni Graz
- Brunner Thomas Baptist
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- BACKGROUND: The study was done to compare treatment and long-term outcomes of neoadjuvant chemoradiation (neoCRT) and perioperative chemotherapy (periCTX) in patients with surgically treated esophageal adenocarcinoma. METHODS: An analysis of 105 patients with esophageal adenocarcinoma undergoing neoCRT (n = 58) or periCTX (n = 47) and esophagectomy between 2000 and 2012 was carried out. RESULTS: The overall median survival was 5.97 years. Postoperative morbidity and in-hospital mortality occurred in 74%/7% of the patients the neoCRT group and in 53%/0% of the patients in the periCTX group (P = 0.03/P = 0.08). Total or subtotal histological tumor response after neoadjuvant treatment and esophagectomy was found in 59% after neoCRT and 30% after periCTX (P < 0.01). Three- and five-year survival rates were 52%/45% for neoCRT and 68%/63% for periCTX (P = 0.05). PeriCTX was identified as an independent predictor of survival (RR2.6; 95% CI 1.3-5.1; P < 0.01). CONCLUSION: A higher rate of histologic response to neoCRT compared to histologic response following the preoperative cycles of periCTX does not translate to a benefit in overall survival. PeriCTX offers a decreased incidence of treatment-related morbidity and mortality and at least equal results in terms of survival compared to neoCRT in patients with locally advanced esophageal adenocarcinoma.
- Find related publications in this database (using NLM MeSH Indexing)
- Actuarial Analysis - administration & dosage
- Adenocarcinoma - drug therapy, mortality, pathology, radiotherapy, surgery, therapy
- Adult - administration & dosage
- Aged - administration & dosage
- Antineoplastic Combined Chemotherapy Protocols - therapeutic use
- Chemoradiotherapy, Adjuvant - administration & dosage
- Chemotherapy, Adjuvant - administration & dosage
- Esophageal Neoplasms - drug therapy, mortality, pathology, radiotherapy, surgery, therapy
- Esophagectomy - adverse effects, mortality
- Female - administration & dosage
- Germany - epidemiology
- Hospital Mortality - administration & dosage
- Humans - administration & dosage
- Kaplan-Meier Estimate - administration & dosage
- Male - administration & dosage
- Middle Aged - administration & dosage
- Multivariate Analysis - administration & dosage
- Neoadjuvant Therapy - methods
- Neoplasm Grading - administration & dosage
- Neoplasm Staging - administration & dosage
- Postoperative Complications - diagnosis, epidemiology, etiology
- Proportional Hazards Models - administration & dosage
- Treatment Outcome - administration & dosage
- Find related publications in this database (Keywords)
- esophageal cancer
- adenocarcinoma
- esophagectomy
- survival
- chemotherapy
- chemoradiation